Cross-talk between β-adrenergic stimulation and estrogen receptors: Isoproterenol inhibits 17β-estradiol-induced gene transcription in A7r5 cells

Journal of Cardiovascular Pharmacology

Volumn 42, Issue 2, 2003, Pages 266-274

  Walters, Marian R ^a   Sharma, Rashmi ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

adrenergic agonist; A7r5 cells; Estrogen receptor; Isoproterenol; Vascular smooth muscle cells

Indexed keywords

ADRENOMEDULLIN; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BETA GALACTOSIDASE; CELL NUCLEUS RECEPTOR; ESTRADIOL; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ISOPRENALINE; LUCIFERASE; LYSINE; PROPANOL; TRANSCRIPTION FACTOR;

ADENOVIRUS; ADRENERGIC STIMULATION; ANIMAL CELL; ARTICLE; CARDIOVASCULAR RESPONSE; CELL TYPE; CONTROLLED STUDY; ENZYME INHIBITION; ESTROGEN RESPONSIVE ELEMENT; GENE EXPRESSION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HYPERTENSION; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPORTER GENE; VASCULAR SMOOTH MUSCLE;

ADRENERGIC BETA-AGONISTS; CELLS, CULTURED; DRUG INTERACTIONS; ESTRADIOL; GENE EXPRESSION REGULATION; GENES, REPORTER; ISOPROTERENOL; MUSCLE, SMOOTH, VASCULAR; RECEPTORS, ESTROGEN;

EID: 0042804859     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200308000-00017     Document Type: Article

References (56)

1. Kahonen M, Tolvanen JP, Sallinen K, et al. Influence of gender on control of arterial tone in experimental hypertension. Am J Physiol. 1998;275:H15-H21.
2. Zubin P, Defagot C. Effect of ovarian steroids on hypothalamic norepinephrine-induced adenylate cyclase activity. Can J Physiol Pharmacol. 1994;72:1299-1303.
3. Bell DR, Rensberger HJ, Koritnik DR, et al. Noradrenergic vasorelaxation of porcine coronary arteries is enhanced by direct, acute exposure to 17 beta-estradiol. Gen Pharmacol. 1995;26:1289-1294.
4. Brauer MM, Bumstocks G. Expression of beta-adrenergic receptors in the rat uterus: effects of puberty and oestrogen treatment during prepubertal development. Int J Dev Neurosci. 1998;16:29-39.
5. Honda H, Yamaguchi K, Kogo H. 17Beta-estradiol alters isoproterenol-induced relaxation in rat aortic rings. Jpn J Pharmacol. 1998;77:311-313.
6. Ferrer M, Meyer M, Osol G. Estrogen replacement increases beta-adrenoceptor-mediated relaxation of rat mesenteric arteries. J Vasc Res. 1996;33:124-131.
7. Yono M, Yoshida M, Takahashi W, et al. Effects of ovarian hormones on beta-adrenergic receptor-mediated relaxation in the female rabbit bladder. Urol Res. 2000;28:38-45.
8. Turner MJ, Mier CM, Spina RJ, et al. Effects of age and gender on the cardiovascular responses to isoproterenol. J Geronotol. 1999;54:B393-B400.
9. Mitchell JH, Tate C, Raven P, et al. Acute response and chronic adaptation to exercise in women. Med Sci Sports Exerc. 1995;24:S258-S265.
10. Ruilope LM, Suarez C. How should we treat hypertensive women with cardiac and renal impairment? Am J Hypertens. 1997;10:242S-246S.
11. Svetkey LP, George LK, Tyroler HA, et al. Effects of gender and ethnic group on blood pressure control in the elderly. Am J Hypertens. 1996;9:529-535.
12. Gullestad L, Hallen J, Medbo JI, et al. The effect of acute vs chronic treatment with beta-adrenoceptor blockade on exercise performance, haemodynamic and metabolic parameters in healthy men and women. Br J Clin Pharmacol. 1996;41:57-67.
13. Pedersen SB, Borglum JD, Eriksen EF, et al. Nuclear estradiol binding in rat adipocytes. Regional variations and regulatory influences of hormones. Biochim Biophys Acta. 1991;1093:80-86.
14. Cardinali DP, Gejman PV, Ritta MN. Further evidence of adrenergic control of translocation and intracellular levels of estrogen receptors in rat pineal gland. Endocrinology. 1983;112:492-498.
15. Li HY, Bian JS, Kwan YW, et al. Enhanced responses to 17beta-estradiol in rat heart treated with isoproterenol: involvement of a cyclic AMP-dependent pathway. J Pharmacol Exp Therapy. 2000;293:592-598.
16. Massie BM. Demographic considerations in the selection of antihypertensive therapy. Am J Cardiol. 1987;60:1211-1261.
17. Medical Research Council Working Party. MRC trial of treatment of mild hypertension. Principal results. BMJ. 1985;291:92-104.
18. Massie BM, MacCarthy EP, Ramanathan KB, et al. Diltiazem and propranolol in mild to moderate essential hypertension as monotherapy or with hydrochlorothiazide. Ann Intern Med. 1987;107:150-157.
19. Mallick R, Leader S. Demographic differences in antihypertensive drug prescribing and treatment outcomes [abstract]. Pharmacoepidemiol Drug Safety. 1997;6(suppl 2):S4.
20. Svetkey LP, George LK, Tyroler HA, et al. Effects of gender and ethnic group on blood pressure control in the elderly. Am J Hypertens. 1996;9:529-535.
21. Klungel OH, de Boer A, Paes AHP, et al. Sex differences in antihypertensive drug use: determinants of the choice of medication for hypertension. J Hypertens. 1998;16:1545-1553.
22. Klungel OH, Paes AHP, de Boer A, et al. Sex differences in the medication choice for hypertension in general practice: a study with written case simulations. Pharm World Sci. 2000;22:140-146.
23. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and estrogen/progestin replacement study (HERS) Research Group. JAMA. 1998;280:605-613.
24. Herrington DM. The HERS trial results: paradigms lost? Heart and Estrogen/progestin replacement study. Ann Intern Med. 1999;131:463-466.
25. Farhat MY, Lavigne MC, Ramwell PW. The vascular protective effects of estrogen. FASEB J. 1996;10:615-624.
26. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Eng J Med. 1999;340:1801-1811.
27. Bayard F, Clamens S, Meggetto F, et al. Estrogen synthesis, estrogen metabolism, and functional estrogen receptors in rat arterial smooth muscle cells in culture. Endocrinology. 1995;136:1523-1529.
28. Orimo A, Inoue S, Ikegami A, et al. Vascular smooth muscle cells as target for estrogen. Biochem Biophys Res Comm. 1993;195:730-736.
29. Mendelsohn ME, Karas RH. Estrogen and the blood vessel wall. Curr Opin Cardiol. 1994;9:619-626.
30. O'Malley BW, Schrader WT, Mani S, et al. An alternative ligand-independent pathway for activation of steroid receptors. Recent Prog Horm Res. 1995;50:333-347.
31. Smith CL. Cross-talk between peptide growth factor and estrogen receptor signaling pathways. Biol Reprod. 1998;58:627-632.
32. Katzenellenbogen BS. Estrogen receptors: bioactivities and interactions with cell signalling pathways. Biol Reprod. 1996;54:287-293.
33. Pietras RJ, Arboleda J, Reese DM, et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene. 1995;10:2435-2446.
34. Lee AV, Yee D. Insulin-like growth factors and breast cancer. Biomed Pharmacother. 1995;49:415-421.
35. Gangolli EA, Conneely OM, O'Malley BW. Neurotransmitters activate the human estrogen receptor in a neuroblastoma cell line. J Steroid Biochem Mol Biol. 1997;61:1-9.
36. Walters MR, Smith CL. Mechanisms of estrogen action: understanding estrogen receptor function. In: Spratt D, ed. Endocrinology of Fertility and the Reproductive System. Humana Press. In press.
37. Hodges YK, Tung L, Yan XD, et al. Estrogen receptors α and β: prevalence of estrogen receptor β mRNA in human vascular smooth muscle and transcriptional effects. Circulation. 2000;101:1792-1798.
38. Karas RH, Hodgin JB, Kwoun M, et al. Estrogen inhibits the vascular injury response in estrogen receptor β-deficient female mice. Proc Natl Acad Sci USA. 1999;96:15133-15136.
39. Ying AK, Hassanain HH, Roos CM, et al. Methylation of the estrogen receptor-alpha gene promoter is selectively increased in proliferating human aortic smooth muscle cells. Cardiovasc Res. 2000;46:172-179.
40. Satake N, Shibato S. Potentiation of the relaxing action of isoproterenol by forskolin in rabbit aortic rings: the involvement of beta 2-adrenoceptors. Gen Pharmacol. 1997;28:753-756.
41. Rasmussen H. The calcium messenger system. N Eng J Med. 1986;314:1094-1101.
42. Toyoshima H, Nasa Y, Hashizume Y, et al. Modulation of cAMP-mediated vasorelaxation by endothelial nitric oxide and basal cGMP in vascular smooth muscle. J Cardiovasc Pharmacol. 1998;32:543-551.
43. Cardillo C, Kilcoyne CM, Quyyumi AA, et al. Decreased vasodilator response to isoproterenol during nitric oxide inhibition in humans. Hypertension 30:918-921.
44. Wikstrand J. Primary prevention with β-blockade in patients with hypertension: review of results and clinical implications. J. Cardiovasc Pharmacol. 1990;16(Suppl. 5):S64-S75.
45. Karas RH, Gauer EA, Bieber HE, et al. Growth factor activation of the estrogen receptor in vascular cells occurs via a mitogen-activated protein kinase-independent pathway. J Clin Invest. 1998;101:2851-2861.
46. Zhou H, Zeng G, Zhou A, et al. Adenovirus mediated gene transfer of vascular smooth muscle cells and endothelial cells in vitro. Chin Med J (Engl). 1995;108:493-496.
47. Allgood VE, Zhang Y, O'Malley BW, et al. Analysis of chicken progesterone receptor function and phosphorylation using an adenovirus-mediated procedure for high efficiency DNA transfer. Biochem. 1997;36:224-232.
48. Power RF, Mani SK, Codina J, et al. Dopaminergic and ligand-independent activation of steroid hormone receptors. Science. 1991;254:1636-1639.
49. Hinson JP, Kapas S, Smith DM. Adrenomedullin, a multifunctional regulatory peptide. Endo Rev. 2000;21:138-167.
50. Vandewalle, B., F. Revillion, and J. Lefebre. Functional β-adrenergic receptor in breast cancer cells. J. Cancer Res. Clin. Oncol. 116:303-306.
51. Yasutomo Y, Shimada N, Kimura N, et al. Estradiol up-regulates the stimulatory GTP-binding protein expression in the MCF-7 human mammary carcinoma cell line. FEBS Lett. 1993;322:25-29.
52. Firulli AB, Kelly-Roloff L, Koteliansky VE, et al. A comparative molecular analysis of four rat smooth muscle cell lines. In Vitro Cell Dev Biol Anim. 1998;34:217-226.
53. Gollasch M, Hasse H, Ried C, et al. L-type calcium channel expression depends on the differentiated state of vascular smooth muscle cells. FASEB J. 1998;12:593-601.
54. Meier KE, Gause KC, Wisehart-Johnson AE, et al. Effects of propranolol on phosphatidate phosphohydrolase and mitogen-activated protein kinase activities in A7r5 vascular smooth muscle cells. Cell Signal. 1998;10:415-426.
55. Hirata Y, Tomita M, Ikeda M. Characterization of alpha- and beta-adrenergic and angiotensin receptors in cultured vascular smooth muscle cells of rat aorta. Jpn Circ J. 1985;49:1043-1051.
56. 2+ current by isoprenaline, carbachol and phorbol ester in cultured rat aortic vascular smooth muscle (A7r5) cells. Gen Pharmacol. 1995;26:369-379.